Custom In Vivo Tumor Model Services

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

SGC-7901 Vincristine-Resistant Gastric Cancer MDR Model Service

Fig 1: SGC-7901 Vincristine-Resistant Gastric Cancer MDR Model preclinical research.

The SGC-7901 Vincristine-Resistant Gastric Cancer MDR Model Service provides a well-characterized in vitro and in vivo platform for studying multidrug resistance (MDR) and evaluating candidate reversal strategies in gastric cancer. As a preclinical CRO dedicated to tumor modeling, Alfa Cytology delivers end-to-end support for this service—from vincristine-pulse selection and resistance index verification to xenograft establishment and pharmacodynamic readouts—so that researchers can obtain publication-quality, decision-ready resistance data without building the model in-house.

Overview of SGC-7901 Vincristine-Resistant Gastric Cancer MDR Model

The SGC-7901 vincristine-resistant gastric cancer MDR model is built on SGC-7901, a human gastric adenocarcinoma cell line that has been exposed to stepwise-increasing concentrations of vincristine until a stable resistant subline—commonly designated SGC-7901/VCR—is obtained. Once established, the resistant cells no longer respond only to vincristine: they display cross-resistance to a broad spectrum of structurally unrelated agents, including adriamycin, cisplatin, etoposide, mitomycin C, and 5-fluorouracil. This cross-resistance pattern is the defining feature of the classical multidrug resistance phenotype and closely mimics the clinical situation in which gastric tumors stop responding to first-line combination chemotherapy.

Fig 2: Reference figures for SGC-7901 Vincristine-Resistant Gastric Cancer MDR Model. Fig 1. lncRNA-mediated MDR mechanism in the SGC7901 vincristine-resistant MDR model: MDR1 and MRP1 transporters on the cell membrane efflux chemotherapeutic drugs; ROR/ANRIL/DANCR lncRNAs sustain efflux, while BLACAT1/MRUL/CASC9 act through miR-361 to promote MDR. (Wang, Shuai, et al., 2020)

Mechanistically, the model is dominated by ATP-binding cassette (ABC) transporter-mediated drug efflux. ABCB1 (P-glycoprotein, encoded by the MDR1 gene) is markedly overexpressed in SGC-7901/VCR cells and pumps vincristine and other substrates out of the cell, lowering intracellular drug accumulation; multidrug resistance-associated protein 1 (MRP1) and major vault protein (MVP) are also frequently up-regulated. Beyond efflux, the resistant phenotype is reinforced by altered apoptotic signaling (such as Bcl-2 elevation), enhanced DNA repair and detoxification pathways, and cell-cycle redistribution. Because these layers of resistance can be measured at the molecular, cellular, and whole-tumor levels, the SGC-7901/VCR model—both as cultured cells and as subcutaneous xenografts in immunodeficient mice—serves as a standard preclinical tool for dissecting MDR mechanisms and for screening chemo-sensitizers and next-generation gastric cancer therapeutics.

Principles of SGC-7901 Vincristine-Resistant Gastric Cancer MDR Model Construction

Construction of the model relies on the principle of selective pressure: a drug-sensitive parental population is repeatedly exposed to vincristine at concentrations that kill most cells, while rare variants carrying pre-existing or induced resistance mechanisms survive, expand, and gradually dominate the culture. Intermittent, stepwise dose escalation—rather than a single high-dose challenge—enriches for stable, heritable resistance with minimized clonal bias and preserves enough viable cells at each stage for the population to recover. The surviving subline is then characterized by resistance index (RI), cross-resistance profiling, transporter expression, and efflux function before it is considered qualified for downstream study.

Principle / Parameter	Detailed Description
Selection strategy	Continuous or intermittent exposure of parental SGC-7901 cells to vincristine, with the dose increased stepwise (e.g., starting near 0.05–0.2 mg/L and escalating in small increments every 1–2 weeks) until a target maintenance concentration is reached.
Stable phenotype maintenance	Resistant cells are routinely cultured in vincristine-containing medium (commonly 0.5–1.0 µg/mL) to maintain the MDR phenotype, and are passaged in drug-free medium for about two weeks before sensitivity or mechanistic assays.
Core molecular basis	Overexpression of ABCB1/P-glycoprotein (MDR1 gene) is the hallmark; MRP1, MVP/lung resistance-related protein, and altered apoptosis regulators (Bcl-2, caspase-3) contribute to and stabilize the phenotype.
Drug efflux function	P-glycoprotein actively extrudes vincristine and other substrates (e.g., rhodamine 123, adriamycin), reducing intracellular accumulation; efflux can be blocked by verapamil or other P-gp inhibitors as a functional validation.
Cross-resistance spectrum	SGC-7901/VCR shows reduced sensitivity to structurally unrelated agents such as adriamycin, cisplatin, etoposide, mitomycin C, and 5-fluorouracil, recapitulating clinical multidrug resistance.
Resistance quantification	Resistance is expressed as the resistance index (RI = IC₅₀ of resistant cells / IC₅₀ of parental cells), typically determined by MTT or CCK-8 assays; a stable RI markedly above 1 (often tens-fold for vincristine) confirms successful selection.
Phenotype validation	Verification combines cell viability assays, P-gp/MRP1 expression by western blot, qRT-PCR or flow cytometry, intracellular drug accumulation assays, and cell-cycle or apoptosis analysis.
In vivo extension	Validated resistant cells (or resistant tumor fragments) are implanted subcutaneously into immunodeficient mice to establish vincristine-resistant xenografts, allowing MDR and its reversal to be studied at the whole-tumor level.

Our Services

Leveraging optimized pulse-selection protocols and stringent quality control at every passage, Alfa Cytology offers the SGC-7901 vincristine-resistant gastric cancer MDR model as a turnkey preclinical solution: resistance is induced and maintained under controlled conditions, confirmed by resistance-index and cross-resistance profiling, and extended into immunodeficient-mouse xenografts when a whole-organism readout is required, giving clients a reliable, mechanism-grounded system for MDR mechanism studies and chemosensitizer screening.

Workflow of SGC-7901 Vincristine-Resistant Gastric Cancer MDR Model Construction

Model construction follows a standardized, quality-controlled pipeline that moves from parental cell expansion to a fully validated resistant phenotype, with optional xenograft extension. Each stage is monitored by growth assessment and molecular checks so that drift, contamination, or loss of resistance is detected early. The typical workflow comprises the following steps:

Parental cell preparation and baseline profiling: SGC-7901 cells are revived, authenticated, and expanded under standard conditions; baseline IC₅₀ values for vincristine and reference drugs are measured by MTT/CCK-8 assay to establish the parental sensitivity profile.
Initiation of vincristine selection: Cells in mid-log growth are transferred to medium containing a low, sub-lethal vincristine concentration (e.g., 0.05–0.2 mg/L) and monitored daily for morphology, confluence, and viability.
Stepwise dose escalation: Once the culture recovers stable growth, the vincristine concentration is raised incrementally (typically by 0.05–0.1 mg/L every 1–2 weeks), with medium refreshed every 2–3 days, until the target maintenance level (about 0.8–1.0 mg/L) is tolerated.
Stabilization and drug-free recovery: The selected population is passaged continuously at the maintenance dose for several weeks to fix the resistant phenotype; before assays, cells are cultured in drug-free medium for roughly two weeks to exclude residual drug carryover.
Resistance and cross-resistance characterization: IC₅₀ values of the resistant subline versus the parental line are compared to calculate the resistance index, and sensitivity to adriamycin, cisplatin, etoposide, mitomycin C, and 5-fluorouracil is profiled to confirm multidrug resistance.
Molecular and functional validation: P-glycoprotein and MRP1 expression are examined by qRT-PCR, western blot, and flow cytometry; rhodamine 123 or adriamycin accumulation assays with and without verapamil verify transporter-mediated efflux activity.
Xenograft establishment (optional: in vivo stage). Validated SGC-7901/VCR cells (typically 5 × 10⁶ cells per mouse, often mixed 1:1 with Matrigel) are inoculated subcutaneously into immunodeficient mice, and resistant tumors are passaged in vivo to generate a stable resistant xenograft line.
Quality control release: Mycoplasma testing, cell-line authentication, growth-curve documentation, and a final resistance-index report are compiled, after which the model is released for client studies.

Fig 3: Workflow for the establishment of SGC-7901 Vincristine-Resistant Gastric Cancer MDR Models. Fig 2. SGC-7901 Vincristine-Resistant Gastric Cancer MDR Model Construction Workflow.

Case Study-SGC-7901 Vincristine-Resistant Gastric Cancer MDR Model Development

In a representative preclinical engagement, the Alfa Cytology team induced and validated a vincristine-resistant SGC-7901 subline for a client investigating candidate MDR reversal agents. Following stepwise selection, the resistant cells exhibited a markedly elevated resistance index together with cross-resistance to several standard gastric cancer agents, and the phenotype was corroborated at the molecular level by up-regulated P-glycoprotein expression and verapamil-sensitive drug efflux. The validated subline was subsequently used in chemosensitivity and combination-treatment experiments, and corresponding resistant xenografts were established to confirm the findings in an in vivo setting. Detailed data packages from this and similar programs can be shared upon request under appropriate confidentiality agreements.

Fig 4: Case Study-SGC-7901 Vincristine-Resistant Gastric Cancer MDR Model Development.

Why Choose Alfa Cytology?

Alfa Cytology combines disciplined, literature-aligned model construction with rigorous quality control, so every SGC-7901 vincristine-resistant MDR model delivered is stable, well-documented, and ready for immediate study use. Key reasons to work with us include:

Standardized stepwise-selection protocol that produces stable, heritable resistance with defined resistance indices.
Multi-level validation covering cross-resistance profiling, transporter expression, and functional efflux assays.
Seamless in vitro-to-in vivo translation with validated resistant xenografts in immunodeficient mice.
Experienced preclinical team providing study design, assay selection, and data interpretation support.
Stringent quality control, including mycoplasma testing, cell authentication, and documented passage history.
Flexible, confidential engagement models with milestone-based reporting and rapid project turnaround.

Contact Us

If you are planning multidrug resistance studies or chemosensitizer screening programs, we invite you to contact us to discuss how the SGC-7901 vincristine-resistant gastric cancer MDR model can accelerate your preclinical research. Reach out to the Alfa Cytology team today for a customized proposal, timeline, and quotation tailored to your study goals.

Reference

Wang, Shuai, et al. "lncRNA ROR promotes gastric cancer drug resistance." Cancer Control 27.1 (2020): 1073274820904694.

For research use only. Not intended for any clinical use.